Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13109MR)

This product GTTS-WQ13109MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13109MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1232MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ1303MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ7903MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ355MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ6605MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ2648MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ12367MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ5662MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDX-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW